PHD Biosciences

PHD Biosciences

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.8M

Overview

Founded in 2011, PHD Biosciences is a private, commercial-stage biotech developing prescription and non-prescription products in oncology and immunology. The company boasts a seasoned leadership team with proven track records in drug development and commercialization, and has secured significant non-dilutive funding to advance its programs. PHD operates with a lean, project-focused model, aiming to translate its scientific innovations into marketed products through strategic development and partnerships.

OncologyImmunology

Technology Platform

Expertise in advanced chemistry and polymer-based drug delivery systems, particularly for topical and systemic applications, including novel methodologies for designing moieties and nanoparticle self-assembly.

Funding History

1
Total raised:$1.8M
Seed$1.8M

Opportunities

The large and growing global markets for oncology and immunology therapeutics present a major opportunity for successful drug approvals.
Additionally, leveraging core drug development expertise to create non-prescription products offers a parallel path to revenue with potentially faster development cycles and lower regulatory hurdles.

Risk Factors

Key risks include clinical trial failure of lead pipeline assets, intense competition in core therapeutic areas from larger companies, and operational dependency on a small, key leadership team.
Regulatory setbacks also pose a constant threat to development timelines.

Competitive Landscape

PHD operates in the highly competitive oncology and immunology sectors, competing against large pharmaceutical companies and well-funded biotechs. Its differentiation likely hinges on its specific drug delivery technology and the development efficiency afforded by its experienced, lean team.